Table 1 Comparison of clinical and pathological data of patients with anti-GBM disease with and without glomerular C1q deposition
From: Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease
| Ā | With C1q deposition (nā=ā7) | Without C1q deposition (nā=ā18) | p |
|---|---|---|---|
Age (years) | 43.7āĀ±ā11.8 | 27.2āĀ±ā11.9 | 0.005 |
Gender (male/female) | 6/1 | 16/2 | 1.000 |
Hydrocarbon exposure | 1/7 (14.3%) | 2/16 (12.5%) | 1.000 |
Prodromal infection | 2/7 (28.6%) | 8/18 (44.4%) | 0.653 |
Smoker | 3/7 (42.9%) | 8/18 (44.4%) | 1.000 |
Hemoptysis | 4/7 (57.1%) | 8/18 (44.4%) | 0.673 |
Oliguria/anuria | 4/7 (57.1%) | 10/18 (55.6%) | 1.000 |
Gross hematuria | 6/7 (85.7%) | 6/18 (33.3%) | 0.03 |
Nephrotic syndrome | 2/3 (66.7%) | 4/8 (50%) | 1.000 |
Serum creatinine (Ī¼mol/L) | 914.3āĀ±ā161.3 | 1021.3āĀ±ā402.9 | 0.353 |
Interval from onset (days) | 48.6āĀ±ā40.0 | 48.5āĀ±ā33.3 | 0.998 |
Level of anti-GBM antibodies (U/mL) | 88.0āĀ±ā49.9 | 88.8āĀ±ā43.0 | 0.969 |
ANCA positive | 1/7 (14.3%) | 1/18 (5.6%) | 0.490 |
Hemoglobin (g/L) | 89.6āĀ±ā25.1 | 78.2āĀ±ā29.5 | 0.377 |
Percentage of crescents in glomeruli (%) | 91.0 (77.0-100.0) | 100 (88.3-100.0) | 0.386 |
āCellular crescents (%) | 75.0 (50.0-100.0) | 75.0(24.5-89.5) | 0.389 |
āFibrocellular crescents (%) | 25.0 (0ā50) | 25.0 (10.5-70.0) | 0.336 |
āFibrotic crescents (%) | 0 | 0 | 0.961 |
Anti-C1q antibody positive | 4/7 (57.1%) | 11/18 (61.1%) | 1.000 |
Level of anti-C1q antibodies (relative OD value) | 0.210āĀ±ā0.05 | 0.245āĀ±ā0.06 | 0.301 |
Renal survival (1Ā year) | 0/7 (0) | 2/18 (11.1%) | 1.000 |
Patient survival (1Ā year) | 3/7 (42.9%) | 15/18 (83.3%) | 0.066 |